Vitalik Buterin, co-founder of Ethereum, published this March 17 his support for the development of “open source vaccines” whose objective would be to allow open participation in the analysis and manufacturing of the vaccine. The announcement is framed within the agenda “d/acc” (English acronym decentralized accelerationdecentralized acceleration) from the developer, as stated that “the full d/acc roadmap is underway.”
The vaccine that is made reference It is PVX-001, a candidate against COVID-19 developed by PopVax, an Indian biotechnology startup. According to reported its founder, Soham Sankaran, Vitalik finances the PopVax project through Balvi, his philanthropic fund, with more than “USD 15 million” in research agreements.
As Sankaran explained, the financing was conditional on a critical commitment: that the vaccine was completely open source. The clinical batch of PVX-001 has already been manufactured and will enter clinical trials in Australia “in the coming months”, assured Sankaran.
Vitalik’s philosophy driving the PopVax open source project
For the co-founder of Ethereum, an open source vaccine manufactured in India and replicable by any laboratory in the world is the type of technology that d/acc should promote, since it would be decentralized and accessible without dependencies on a few corporations.
The concept “d/acc” was first introduced by Vitalik in November 2023 in his rehearsal «My techno-optimism»published on his personal blog, as a response and counterproposal to the movement “e/acc” (effective accelerationism or effective accelerationism).
The proposal “e/acc”which at the time was gaining traction in Silicon Valley among investors and founders of AI startups, pointed to a techno-optimistic ideology that advocated accelerating technological progress without restrictionsespecially in artificial intelligence, to solve global human problems.
On the contrary, the intention of Vitalik’s initiative is selectively accelerate technological progressprioritizing, according to himself, innovations that tilt the balance between offensive and defensive capabilities towards the defensive side, without concentrating power in central authorities or in a few corporations.
In biotechnology, this translates into promoting open source research, globally distributed manufacturing, and broad access, rather than relying on monopolistic patents controlled by Big Pharma.
Thus, PopVax represents so far a concrete and advanced example of this philosophy applied to global health.
A model that challenges the traditional pharmaceutical scheme
PopVax, founded in 2021, develops vaccines against diseases such as COVID-19, tuberculosis, hepatitis C, malaria and different types of cancer.
To do this, as described by Sankaran, it combines generative artificial intelligence (AI) to design immunogens (the proteins that activate the immune response) with its own messenger RNA (mRNA) platform. The latter is similar to the technology used by companies such as Pfizer and Moderna, but aimed at being faster and cheaper to produce.
In addition to Balvi, Sankaran indicates that the project received funding from the Gates Foundation and other philanthropic organizations.
The central element of the PopVax project is not only the vaccine but its distribution model. PVX-001 is open source: once the clinical trial phase is completed, the company plans to publish the complete design and manufacturing process so that any laboratory in the world can replicate it without paying royalties.
This scheme directly contrasts with the big pharmaceutical model, where Patents restrict who can make a vaccine and at what price.
The question this model raises is whether an open source vaccine, without the financial backing or regulatory infrastructure of a traditional pharmaceutical company, can make it all the way to approval and mass distribution. PVX-001 has just entered the clinical trial phase, the first of several regulatory filters that can take years.
Finally, Sankaran projects bring vaccines to clinical trials before the end of 2027 against tuberculosis, hepatitis C, malaria and group A streptococcus, diseases that, according to their estimates, cause 2.4 million deaths annually.